CoChat

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.

Abstract

Purpose: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with long-term outcome. We aimed to find rational combinations that potentiate cetuximab efficacy by disrupting adaptive dependencies on antiapoptotic molecules (BCL2, BCL-XL, MCL1). Experimental Design: Experiments were conducted in patient-derived xenografts (PDX) and organoids (PDXO). Apoptotic priming was analyzed by BH3 profiling. Proapoptotic and antiapoptotic protein complexes were evaluated by co-immunoprecipitation and electroluminescence sandwich assays. The effect of combination therapies was assessed by caspase activation in PDXOs and by monitoring PDX growth. Results: A population trial in 314 PDX cohorts, established from as many patients, identified 46 models (14.6%) with appreciable (>50% tumor shrinkage) but incomplete response to cetuximab. From these models, 14 PDXOs were derived. Cetuximab primed cells for apoptosis, but only concomitant blockade of BCL-XL precipitated cell death. Mechanistically, exposure to cetuximab induced upregulation of the proapoptotic protein BIM and its sequestration by BCL-XL. Inhibition of BCL-XL resulted in displacement of BIM, which was not buffered by MCL1 and thereby became competent to induce apoptosis. In five PDX models, combination of cetuximab and a selective BCL-XL inhibitor triggered apoptosis and led to more pronounced tumor regressions and longer time to relapse after treatment discontinuation than cetuximab alone. Conclusions: In mCRC tumors that respond to cetuximab, antibody treatment confers a synthetic-lethal dependency on BCL-XL. Targeting this dependency unleashes apoptosis and increases the depth of response to cetuximab.

Overview

CoChat Summary

TL;DR

In patient-derived models of metastatic colorectal cancer, cetuximab primes cells for apoptosis and upregulates BIM, but BCL-XL sequesters BIM and prevents cell death. Adding BCL-XL blockade unleashes apoptosis, deepens cetuximab response, and delays relapse in PDX models.

Key findings

  • In a population trial of 314 mCRC PDXs, only 46 models (14.6%) showed >50% mean tumor volume reduction after 3 weeks of cetuximab; all cetuximab-sensitive models lacked KRAS, NRAS, and BRAF resistance-driving mutations.
  • Cetuximab increased apoptotic priming in PDXOs and upregulated BIM, which was preferentially sequestered by BCL-XL; selective BCL-XL inhibition with A-1331852 or navitoclax plus cetuximab triggered massive caspase 3/7 activation in 14 cetuximab-sensitive PDXOs, whereas the BCL2 inhibitor venetoclax did not enhance cetuximab.
  • In five cetuximab-sensitive PDXs, cetuximab plus A-1331852 produced deeper tumor shrinkage in two models, reduced cancer cell density in others, and led to longer time to relapse after treatment discontinuation than cetuximab alone.
  • In cetuximab-resistant PDXOs, cetuximab did not induce BIM upregulation, and adding cetuximab to BCL-XL inhibition was inconsequential.

Methods

  • Patient-derived xenografts (PDX) and organoids (PDXO) from mCRC; a 314-PDX population trial identified cetuximab-responsive models, 14 PDXOs were derived, and five PDX models were used for in vivo combination testing.
  • Dynamic BH3 profiling measured apoptotic priming; co-immunoprecipitation and Meso Scale Discovery assays quantified BIM:BCL-XL and BIM:MCL1 complexes; viability, caspase 3/7, qRT-PCR, IHC, and morphometric analyses were used.
  • Statistical analyses included two-tailed Welch t test, one-way ANOVA with Šidák correction, Spearman correlation, and log-rank (Mantel–Cox) test, with significance set at P < 0.05.

Limitations

  • The paper states it did not explore the reasons underlying modulation of MCL1:BIM stoichiometry by navitoclax and cetuximab.
  • The paper notes that caliper-based tumor measurements are not precise with very small masses.
  • The paper states that navitoclax development faces obstacles due to high incidence of on-target thrombocytopenia from BCL-XL inhibition in platelets; evident from the text, the in vivo combination efficacy was assessed in five PDX models and remains preclinical.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-2550

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. EGFR blockade increases apoptotic priming and induces preferential binding of upregulated BIM to BCL-XL. A, Cetuximab response after 3 weeks of treatment (20 mg/kg, intraperitoneal injection twice a week) compared with tumor volume the day before treatment initiation in 314 mCRC PDX models (n = 6 or 12 mice for each bar, depending on whether initial engraftment was successful in 1 or 2 mice). Response categories were arbitrarily defined: regression (below the lower dotted line, −50%); progressive disease (above the upper dotted line, +35%); and disease stabilization (between the dotted lines). Wild-type denotes cases with no mutations in KRAS, NRAS, or BRAF. Selected models denotes cases from which PDXOs were generated. B, Scatter plot showing simple linear regression of cetuximab response profiles in 13 selected PDXOs (percentage of cell viability reduction relative to untreated controls) and in their corresponding PDXs of origin (percentage of tumor volume variation after 3 weeks of treatment compared with tumor volume the day before treatment initiation). Organoids were treated with cetuximab (20 μg/mL) for 1 week, then cell viability was assessed by ATP content (Cell Titer Glo assay). PDXs were treated with cetuximab as described in A. Dotted lines indicate the 95% confidence bands of the best-fit line. Statistical analysis by Spearman correlation coefficient. C, Delta priming response to BIM (0.003 μmol/L) and Bmf-Y (1 μmol/L) peptides in 10 PDXOs after cetuximab treatment (24 hours, 20 μg/mL). Delta priming = % cytochrome c losscetuximab − % cytochrome c lossuntreated. Each bar represents the average of two independent experiments or, for CRC0078, a single experiment. Western blot analysis with the indicated antibodies in whole-cell extracts (D) or after immunoprecipitation with antibodies agains BCL-XL (E) or MCL1 (F) in four PDXOs. Organoids were treated with 20 μg/mL cetuximab for 72 hours. NT, untreated control; Cet, cetuximab; Vinc, vinculin (loading control); Ctrl, BT-474 cell extracts as a positive control for antibody specificity (D) or beads without capture antibody as a negative control for immunoprecipitates (E and F). Images from a second experiment on independent biological replicates are shown in Supplementary Fig. S1.
Figure 1. EGFR blockade increases apoptotic priming and induces preferential binding of upregulated BIM to BCL-XL. A, Cetuximab response after 3 weeks of treatment (20 mg/kg, intraperitoneal injection twice a week) compared with tumor volume the day before treatment initiation in 314 mCRC PDX models (n = 6 or 12 mice for each bar, depending on whether initial engraftment was successful in 1 or 2 mice). Response categories were arbitrarily defined: regression (below the lower dotted line, −50%); progressive disease (above the upper dotted line, +35%); and disease stabilization (between the dotted lines). Wild-type denotes cases with no mutations in KRAS, NRAS, or BRAF. Selected models denotes cases from which PDXOs were generated. B, Scatter plot showing simple linear regression of cetuximab response profiles in 13 selected PDXOs (percentage of cell viability reduction relative to untreated controls) and in their corresponding PDXs of origin (percentage of tumor volume variation after 3 weeks of treatment compared with tumor volume the day before treatment initiation). Organoids were treated with cetuximab (20 μg/mL) for 1 week, then cell viability was assessed by ATP content (Cell Titer Glo assay). PDXs were treated with cetuximab as described in A. Dotted lines indicate the 95% confidence bands of the best-fit line. Statistical analysis by Spearman correlation coefficient. C, Delta priming response to BIM (0.003 μmol/L) and Bmf-Y (1 μmol/L) peptides in 10 PDXOs after cetuximab treatment (24 hours, 20 μg/mL). Delta priming = % cytochrome c losscetuximab − % cytochrome c lossuntreated. Each bar represents the average of two independent experiments or, for CRC0078, a single experiment. Western blot analysis with the indicated antibodies in whole-cell extracts (D) or after immunoprecipitation with antibodies agains BCL-XL (E) or MCL1 (F) in four PDXOs. Organoids were treated with 20 μg/mL cetuximab for 72 hours. NT, untreated control; Cet, cetuximab; Vinc, vinculin (loading control); Ctrl, BT-474 cell extracts as a positive control for antibody specificity (D) or beads without capture antibody as a negative control for immunoprecipitates (E and F). Images from a second experiment on independent biological replicates are shown in Supplementary Fig. S1.CC BY-NC-ND · PubMed Central
Figure 2. Selective BCL-XL inhibition potentiates the therapeutic effect of EGFR blockade by unleashing apoptosis in cetuximab-sensitive organoids. Evaluation of cell viability based on ATP content (A and B) and evaluation of apoptosis based on caspase 3/7 activity (C and D) in 14 cetuximab-sensitive and four cetuximab-resistant PDXOs treated with the indicated drugs at the following concentrations: cetuximab, 20 μg/mL; navitoclax, 1 μmol/L; A-1331852, 0.5 μmol/L; venetoclax, 1 μmol/L. Organoids were treated for 48 hours in four independent experiments (cetuximab-sensitive PDXOs in A and C, top) or three independent experiments (cetuximab-resistant PDXOs in A and C, bottom; all models in B and D). For each experiment, results are shown as the means of four biological replicates (cetuximab-sensitive PDXOs in A and C, top) or five biological replicates (cetuximab-resistant PDXOs in A and C, bottom; all models in B and D). Caspase 3/7 activity signals were normalized against viable cells, which were treated in parallel with the same modalities and assessed by ATP content. NT, untreated control; Cet, cetuximab; Nav, navitoclax; Ven, venetoclax; A-1331, A-1331852. Results of statistical analysis are reported in Supplementary Fig. S2.
Figure 2. Selective BCL-XL inhibition potentiates the therapeutic effect of EGFR blockade by unleashing apoptosis in cetuximab-sensitive organoids. Evaluation of cell viability based on ATP content (A and B) and evaluation of apoptosis based on caspase 3/7 activity (C and D) in 14 cetuximab-sensitive and four cetuximab-resistant PDXOs treated with the indicated drugs at the following concentrations: cetuximab, 20 μg/mL; navitoclax, 1 μmol/L; A-1331852, 0.5 μmol/L; venetoclax, 1 μmol/L. Organoids were treated for 48 hours in four independent experiments (cetuximab-sensitive PDXOs in A and C, top) or three independent experiments (cetuximab-resistant PDXOs in A and C, bottom; all models in B and D). For each experiment, results are shown as the means of four biological replicates (cetuximab-sensitive PDXOs in A and C, top) or five biological replicates (cetuximab-resistant PDXOs in A and C, bottom; all models in B and D). Caspase 3/7 activity signals were normalized against viable cells, which were treated in parallel with the same modalities and assessed by ATP content. NT, untreated control; Cet, cetuximab; Nav, navitoclax; Ven, venetoclax; A-1331, A-1331852. Results of statistical analysis are reported in Supplementary Fig. S2.CC BY-NC-ND · PubMed Central
Figure 3. Dual blockade of EGFR and BCL-XL leads to BIM release from both BCL-XL and MCL1. Four different PDXOs were treated for 8 hours with the indicated drugs and BIM binding to BCL-XL (A) or MCL1 (B) was quantified by MSD assay. Three independent experiments were performed in each PDXO. For each experiment, signals were normalized against the sum of their values and plotted as individual dots connected by lines. A, NT versus Cet, P < 0.0001; NT versus Nav, P < 0.0001; Cet versus Cet + Nav, P < 0.0001. B, NT versus Cet, P > 0.9999; NT versus Nav, P = 0.0002; Cet versus Cet + Nav, P = 0.3443; Nav versus Cet + Nav, P = 0.0248. Statistical analysis by one-way ANOVA followed by Šidák correction. NT, untreated control; Cet, cetuximab; Nav, navitoclax.
Figure 3. Dual blockade of EGFR and BCL-XL leads to BIM release from both BCL-XL and MCL1. Four different PDXOs were treated for 8 hours with the indicated drugs and BIM binding to BCL-XL (A) or MCL1 (B) was quantified by MSD assay. Three independent experiments were performed in each PDXO. For each experiment, signals were normalized against the sum of their values and plotted as individual dots connected by lines. A, NT versus Cet, P < 0.0001; NT versus Nav, P < 0.0001; Cet versus Cet + Nav, P < 0.0001. B, NT versus Cet, P > 0.9999; NT versus Nav, P = 0.0002; Cet versus Cet + Nav, P = 0.3443; Nav versus Cet + Nav, P = 0.0248. Statistical analysis by one-way ANOVA followed by Šidák correction. NT, untreated control; Cet, cetuximab; Nav, navitoclax.CC BY-NC-ND · PubMed Central
Figure 4. Combined inhibition of EGFR and BCL-XL unleashes apoptosis and reduces residual disease in mCRC PDXs. A, Tumor volume changes in PDXs from mice treated with the indicated modalities for 5 weeks. Cetuximab, 20 mg/kg (intraperitoneal injection twice a week); A-1331852, 25 mg/kg (oral gavage 5 days a week). Dots represent volume changes of PDXs from individual mice, and plots show the means ± SD for each treatment arm. n = 9 to 12 animals per each treatment arm. Statistical analysis by two-tailed unpaired t test with Welch correction. B, Microscopic assessment of residual cancer cell burden in PDXs treated with the indicated modalities. Top panels indicate morphometric quantifications (n = 7 to 9 depending on the extent of section area); bottom panels show hematoxilin and eosin staining and visualization of cancer cells by digital segmentation. Statistical analysis by two-tailed unpaired t test with Welch correction. Scale bar, 500 μm. C, Kaplan–Meier survival curves in PDXs following cessation of the indicated treatments. n = 6 to 9 animals per each treatment arm. Statistical analysis by log-rank (Mantel–Cox) test. D, Morphometric quantification of apoptosis (cleaved caspase 3) in PDXs treated for 24 hours with the indicated modalities. After treatment, three tumors from 3 different mice were explanted and subjected to IHC analysis. Each dot represents the value measured in one optical field (20X), with 5 to 10 optical fields per tumor depending on the extent of section area (n = 15–30). The plots show means ± SD. Statistical analysis by two-tailed unpaired t test with Welch correction. Veh, vehicle; Cet, cetuximab; A-1331, A-1331852.
Figure 4. Combined inhibition of EGFR and BCL-XL unleashes apoptosis and reduces residual disease in mCRC PDXs. A, Tumor volume changes in PDXs from mice treated with the indicated modalities for 5 weeks. Cetuximab, 20 mg/kg (intraperitoneal injection twice a week); A-1331852, 25 mg/kg (oral gavage 5 days a week). Dots represent volume changes of PDXs from individual mice, and plots show the means ± SD for each treatment arm. n = 9 to 12 animals per each treatment arm. Statistical analysis by two-tailed unpaired t test with Welch correction. B, Microscopic assessment of residual cancer cell burden in PDXs treated with the indicated modalities. Top panels indicate morphometric quantifications (n = 7 to 9 depending on the extent of section area); bottom panels show hematoxilin and eosin staining and visualization of cancer cells by digital segmentation. Statistical analysis by two-tailed unpaired t test with Welch correction. Scale bar, 500 μm. C, Kaplan–Meier survival curves in PDXs following cessation of the indicated treatments. n = 6 to 9 animals per each treatment arm. Statistical analysis by log-rank (Mantel–Cox) test. D, Morphometric quantification of apoptosis (cleaved caspase 3) in PDXs treated for 24 hours with the indicated modalities. After treatment, three tumors from 3 different mice were explanted and subjected to IHC analysis. Each dot represents the value measured in one optical field (20X), with 5 to 10 optical fields per tumor depending on the extent of section area (n = 15–30). The plots show means ± SD. Statistical analysis by two-tailed unpaired t test with Welch correction. Veh, vehicle; Cet, cetuximab; A-1331, A-1331852.CC BY-NC-ND · PubMed Central
Figure 5. EGFR inhibition increases BIM protein levels in vivo, and high BIM abundance is maintained after concomitant inhibition of BCL-XL. Representative images of BIM immunoreactivity in PDXs after treatment for 5 weeks with cetuximab (20 mg/kg, intraperitoneal injection twice a week) or cetuximab plus A-1331852 (25 mg/kg, oral gavage 5 days a week). At the end of treatment, two to three tumors from 2 to 3 different mice were explanted and subjected to IHC analysis. Veh, vehicle; Cet, cetuximab; A-1331, A-1331852. Scale bar, 50 μm.
Figure 5. EGFR inhibition increases BIM protein levels in vivo, and high BIM abundance is maintained after concomitant inhibition of BCL-XL. Representative images of BIM immunoreactivity in PDXs after treatment for 5 weeks with cetuximab (20 mg/kg, intraperitoneal injection twice a week) or cetuximab plus A-1331852 (25 mg/kg, oral gavage 5 days a week). At the end of treatment, two to three tumors from 2 to 3 different mice were explanted and subjected to IHC analysis. Veh, vehicle; Cet, cetuximab; A-1331, A-1331852. Scale bar, 50 μm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 20 Not checked · 87 Own results and interpretations

58 more claims

Create a free account to see all 107 claims and to verify the 32 references still open.

See all claims — free account
  • It may state two separate claims as one. 35
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 50 references

Cited by

See all 30

Metadata

Authors
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., Grassi, E., Trusolino, L., & Bertotti, A.
Affiliations
  • Candiolo Cancer Institute (IT)
  • 3Mauriziano Umberto I Hospital, Torino, Italy.
Corresponding author
Trusolino, Livio
Venue
Clinical Cancer Research
Published
2023-01-09
Volume
29
Issue
6
Pages
1102-1113
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4313830048
Cited by
30
References
50
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 21
FWCI
2.08
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc-nd)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
Funders
  • Associazione Italiana per la Ricerca sul Cancro (Investigator Grant 22802, 5x1000 grant 21091, AIRC/CRUK/FC AECC Accelerator Award 22795, Investigator Grants 20697)
  • HORIZON EUROPE European Research Council (Consolidator Grant 724748 BEAT)
  • Horizon 2020 Framework Programme (754923 COLOSSUS, 731105 EDIReX)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
synthetic lethality, BCL-XL inhibition, cetuximab, metastatic colorectal cancer, EGFR inhibition, building information modeling, Mcl-1, apoptosis, patient-derived xenografts, colorectal cancer organoids, combination therapy, depth of response, RAS wild-type
MeSH terms
Cetuximab, Colonic Neoplasms, Humans, Neoplasm Recurrence, Local, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Apoptosis Regulatory Proteins, bcl-X Protein, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-2550
The paper
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., Grassi, E., Trusolino, L., & Bertotti, A. (2023). Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-2550

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.